Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X SuperDividend ETF (SDIV) vs Zoetis Inc (ZTS) Price & Performance

Global X SuperDividend ETFTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Global X SuperDividend ETF vs Zoetis Inc — how do they compare? Global X SuperDividend ETF trades at $23.9 (market cap $1.17B), while Zoetis Inc trades at $74.24 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 25.8× Global X SuperDividend ETF's market cap, and Zoetis Inc pays a 2.9% dividend while Global X SuperDividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X SuperDividend ETF for 47 Days and Zoetis Inc for 70 Days on average.

SDIVZTS
Market Cap
$1.17B$30.20B
Volume
387,6926,175,327
Sector
Broad Market / FactorHealth
52-Week High
$26.34$147.53
52-Week Low
$22.90$69.09
Typical Hold Time
47 Days70 Days
Enterprise Value
—$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X SuperDividend ETF

SDIV trades at $23.58, down 0.55% with a bearish technical signal from moving averages. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, having lost 66% since inception. Recent institutional buying by Ameritas Advisory contrasts with negative media coverage questioning sustainability of high yields amid capital depreciation.

Outlook remains challenged by structural underperformance versus benchmarks. The high yield attracts income seekers but masks negative growth and volatility risks. Investment case hinges on yield sustainability versus capital preservation, with analyst sentiment cautious given persistent track record of value destruction.

Zoetis Inc

Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.

Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SDIV
15% Buy85% Sell
Avg holding period · 47 Days
ZTS

No sentiment data available yet.

About Global X SuperDividend ETF

SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.

Read more on SDIV →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →